Viral growth assay to evaluate the replicative capacity of HIV-1 isolates

Journal of Virological Methods

Volumn 115, Issue 2, 2004, Pages 199-205

  Nicastri, Emanuele ^b   Sarmati, Loredana ^a   Dori, Luca ^a   Montano, Marco ^a   D'Ettorre, Gabriella ^d   Buonomini, Anna Rita ^a   Parisi, Saverio G ^c   Concia, Ercole ^c   Vullo, Vincenzo ^d   Andreoni, Massimo ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Drug resistance; HIV; Replicative capacity; Viral growth assay

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; CD8 ANTIGEN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; GENE INSERTION; GENE MUTATION; HUMAN; HUMAN CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIROGENESIS; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS 1; INSERTION SEQUENCES;

EID: 10744219720     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2003.09.032     Document Type: Article

References (19)

1. Barbour J.D., Wrin T., Grant R.M., Martin J.N., Segal M.R., Petropoulos C.J., Deeks S.G. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J. Virol. 76:2002;11104-11112.
2. Cozzi-Lepri, A., Phillips, A.N., Miller, V., Katlama, C., Ledergerber, B., Vella, S., Weber, J., Bruun, J.N., Kirk, O., Clotet, B., Lundgrens, J.D., 2003. Changes in viral load in people with virological failure who remain on the same HAART regimen. Antiviral Ther. 8(2), 127-136.
3. d'Ettorre G., Forcina G., Andreotti M., Sarmati L., Palmisano L., Galluzzo C.M., Nicastri E., Mastroianni C.M., Vullo V., Vella S., Andreoni M. Discordant response to antiretroviral therapy: HIV isolation, genotypic mutations, T-cell proliferation and cytokine production. AIDS. 16:2002;1877-1885.
4. Deeks S.G. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. 26(1):2001;S25-S33.
5. Deeks S.G., Wrin T., barbour J., Martin J.N., Hellmann N., Grant R.M., Petropoulos C. Evolution of phenotypic drug susceptibility and viral replication capacity during stable protease inhibitor-based therapy despite incomplete viral suppression. Antiviral Ther. 6(9):2001;S62.
6. Deeks S.G., Hoh R., Grant R.M., Wrin T., Barbour J.D., Narvaez A., Cesar D., Abe K., Hanley M.B., Hellmann N.S., Petropoulos C.J., McCune J.M., Hellerstein M.K. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J. Infect. Dis. 185:2002;315-323.
7. Harrigan P.R., Bloor S., Larder B.A. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J. Virol. 72:1998;3773-3778.
8. Hellmann N.S., Wrin T., Bates M., Grant R., Hicks C., Haubrick R., Petropoulos C.J. Modelling the effect of HIV replication capacity on treatment outcomes. Antiviral Ther. 7:2002;S53.
9. Maguire M.F., Guinea R., Griffin P., Macmanus S., Elston R.C., Wolfram J., Richards N., Hanlon M.H., Porter D.J., Wrin T., Parkin N., Tisdale M., Furfine E., Petropoulos C., Snowden B.W., Kleim J.P. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J. Virol. 76:2002;7398-7406.
10. Mammano F., Petit C., Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag co-evolution in protease inhibitor-treated patients. J. Virol. 72:1998;7632-7637.
11. Martinez-Picado J., Savara A.V., Sutton L., D'Aquila R.T. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 73:1999;3744-3752.
12. Myint, L., Matsuda, M., Matsuda, Z., Yokomaku, Y., Chiba, T., Okano, A., Yamada, K., Sugiura, W., 2002. In: Proceedings of the XI International HIV Drug Resist Workshop: Basic Principles and Clinical Implication, Seville, Spain. Antiviral Ther. 77, 2002 (abstract).
13. Nicastri E., D'Ettorre G., Palmisano L., Parisi S.G., Uccella I., Rianda A., Concia E., Vullo V., Vella S., Andreoni M. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J. Med. Virol. 69:2003;1-6.
14. Nijhuis M., Schuurman R., de Jong D., Erickson J., Gustchina E., Albert J., Schipper P., Gulnik S., Boucher C. Increased fitness of drug resistant HIV protease as a result of acquisition of compensatory mutations during sub optimal therapy. AIDS. 13:1999;2349-2359.
15. Nijhuis M., Deeks S.G., Boucher C. Implications of antiretroviral resistance on viral fitness. Curr. Opin. Infect. Dis. 14:2001;23-28.
16. Sambrook, J., Fritsch, E.F., Maniatis, T., 1989. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
17. Schinazi R.F., Larder B.A., Mellors J. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int. Antiviral News. 8:2000;65-91.
18. Simon V., Vanderhoeven J., Padte N., Murray D., Balfe P., Markowitz M. Characterization of multidrug resistant HIV-1 isolates. Antiviral Ther. 7:2002;S62.
19. Whitcomb J.M., Huang W., Limoli K., Paxinos E., Wrin T., Skowron G., Deeks S.G., Bates M., Hellmann N.S., Petropoulos C.J. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical. AIDS. 16:2002;F41-F47.